ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Pharmaceuticals

Fujifilm invests $930m in Denmark to double bio-drug output

Japanese developer of Avigan expanding facility for production and packaging

Fujifilm is planning a major expansion of biopharmaceutical production at its Denmark factory.

TOKYO -- Fujifilm Holdings, developer of anti-flu treatment Avigan, will invest about 100 billion yen ($928 million) to ramp up production of biopharmaceuticals at its plant in Denmark, the company announced Tuesday, in response to increasing demand for medicines as therapeutic agents.

Toward that end, the Japanese company will double capacity of special cell culture tanks used for making drugs. It also plans to introduce a formulation and packaging facility to process them, thus building a system for integrated production.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more